Cristina Csimma, PharmD, MHP, is a biopharmaceutical executive, independent board director, former CEO, VC, and strategic advisor for multiple biotechnology companies, NIH and patient foundations.
She currently serves as the Executive Chair of the Board of Directors of Caraway Therapeutics, as a Board Director at Seneca Biopharma (formerly Neuralstem Inc), Idera Pharmaceuticals Inc, the T1D Exchange (non-profit Type 1 Diabetes) and on the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee. She was previously the Executive Chair of the Board of Directors of Exonics Therapeutics (acquired by Vertex in 2019), Board Director of Juniper Pharmaceuticals (acquired by Catalent in 2018), Board Director and SAB co-chair of Vtesse Pharma (acquired by Sucampo Pharmaceuticals 2017) and Board Director of Cydan where she was also the founding CEO and President. Other roles included Venture Advisor for NEA and Atlas Ventures, and the NIH External Oversight Committee of the Blueprint Neurotherapeutics Network. Previously, she served as Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures LLC, and held multiple roles in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana Farber Cancer Institute.
Dr. Csimma received her Bachelor of Science and Doctor of Pharmacy degrees from Massachusetts College of Pharmacy, and a Master of Health Professions from Northeastern University.